查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2004806

遗传性血管性水肿治疗市场：2026-2032年全球市场预测（依治疗方法、药物类别、给药途径、分销管道和最终用户划分）

Hereditary Angioedema Therapeutics Market by Treatment Type, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年遗传性血管性水肿治疗市场价值 407.7 亿美元，预计到 2026 年将成长至 434.9 亿美元，年复合成长率为 6.45%，到 2032 年将达到 631.5 亿美元。

主要市场统计数据
基准年 2025 407.7亿美元
预计年份：2026年 434.9亿美元
预测年份 2032 631.5亿美元
复合年增长率 (%) 6.45%

对重新定义遗传性血管性水肿的管理和策略重点的临床、商业性和监管趋势进行了简明扼要且综合的概述。

遗传性血管性水肿的特征是阵发性、可能危及生命的水肿，由缓激肽介导的通路失调引起，至今仍是一个独特的治疗领域。临床治疗已从以医院为中心的急性介入发展为持续性治疗，强调快速按需治疗，并结合积极的预防策略，以降低发作频率和严重程度。新型标靶治疗、不断改进的给药途径以及不断变化的医疗服务体系，正在影响临床决策、与保险公司的谈判以及病患的用药依从性。

近年来，治疗创新、给药方法的改变以及证据的积累，是如何改变遗传性血管性水肿的临床路径和商业性价值的提案？

过去十年间，药物治疗模式、医疗服务体系和患者期望都发生了翻天覆地的变化，所有这些都在重塑遗传性血管性水肿的治疗生态系统。治疗创新已超越传统的血浆替代疗法，涵盖了靶向生技药品和旨在抑制激肽释放酶活性或阻断缓激肽信号传导的小分子化合物。这使得按需治疗和持续预防性护理成为可能。这些进展在为临床医师提供新选择的同时，也提高了在真实临床实务中评估疗效、耐受性和用药依从性的门槛。

本研究评估了近期关税政策调整对遗传性血管性水肿治疗的供应链、製造选择、临床管理和获取途径的连锁反应。

贸易政策和关税框架的调整会对依赖特殊原料的复杂生物製药和治疗药物的供应链经济、产品供应和策略采购决策产生重大影响。影响中间体、低温运输运输和医疗设备配件的关税变化会推高製造商的成本结构，并导致不同分销管道的价格波动。为了因应这些变化，相关人员正在重新审视供应商多元化、区域製造地和库存策略，以确保依赖时效性治疗的患者能够持续获得医疗服务。

透过治疗目标、药理分类、给药途径、分销管道和最终用户护理环境来分析治疗生态系统，以帮助进行策略规划。

此治疗领域的细分透过明确治疗目标、药理学、给药途径、通路和终端用户环境，为商业性和临床决策提供框架。根据治疗类型，重点关注按需治疗和预防策略。按需干预措施包括缓激肽受体拮抗剂、激肽释放酶抑制剂、血浆来源的C1抑制剂和重组C1抑制剂，而预防策略包括单株抗体、口服小分子药物和血浆来源的C1抑制剂。这种治疗类型分类阐明了即时症状控制和长期预防癫痫发作之间的治疗权衡，有助于制定临床治疗方案和个人化治疗计划。

区域医疗保健系统、支付方流程和医疗保健服务模式如何导緻美洲、欧洲、中东和非洲以及亚太地区出现不同的部署模式。

区域差异持续影响遗传性血管性水肿治疗的临床实务模式、监管路径、报销模式和推广速度。在美洲，成熟的专科医疗网络、强大的私人保险公司以及集中的专业中心正在加速新型预防药物的引入，并支持与专科药房的密切合作。区域临床路径强调快速、按需的就医途径，同时结合不断扩大的居家预防项目，这既体现了患者的意愿，也反映了医疗机构减少急诊治疗需求的奖励。

本检验了创新和成熟公司如何透过协调临床差异化、经销伙伴和真实世界数据 (REW) 来确保可持续的商业性竞争力。

在遗传性血管性水肿领域，企业策略日益侧重于差异化的临床特征、创新的给药方法以及提供证据以支持支付方和医疗服务提供者的价值提案。在生物製药领域拥有丰富经验的成熟生物製药公司倾向于利用规模经济、一体化生产结构和现有商业网络来推出单株抗体和重组酶，而规模小规模的生物技术公司则专注于高度标靶化的作用机制、新型口服分子或可实现皮下或居家给药的製剂改进。平台创新者与专业经销商之间的策略合作十分普遍，这种合作将临床差异化与在复杂供应链中执行的能力相结合。

透过协调临床证据、分散式供应链、供应链弹性以及与支付方合作，加快部署速度并保持可及性的实用策略。

行业领导者应优先考虑整合式方法，将治疗差异化与可操作的交付模式以及可靠的证据相结合。首先，投资纵向真实世界研究和病患报告结局 (PRO) 评估工具，以证明其不仅具有临床疗效，还能减少医疗保健使用并改善日常生活功能。这些数据资产有助于加强与支付方的合约谈判，并建立引人入胜的故事，从而确保优先地位，即使临床差异细微。其次，优化产品形式和支援服务，以实现分散式医疗。开发培训模组、远端医疗支援和家庭用药清单可以减少采用障碍并提高用药依从性。

一种透明的、混合的证据整合方法，结合临床文献、相关人员访谈、註册登记和产业分析，以支持策略决策。

本分析所依据的研究结合了对同侪审查的临床文献、监管文件和指南的系统性回顾，以及对临床、支付者和商业相关人员的专家访谈。资料提取优先考虑治疗机制、给药途径、记录的疗效、安全讯号和医疗服务模式。研究整合了来自临床註册和匿名化理赔数据的真实世界信息，揭示了治疗途径和医疗服务地点的变化，而无需依赖专有的市场规模数据集。

本文总结了为什么整合临床创新、供应链韧性和真实世界证据对于将治疗方面的进步转化为可持续的患者获取途径至关重要。

遗传性血管性水肿的治疗格局正处于一个转折点，基于机制的创新、柔软性的给药方式以及新的循证范式正在融合，从而构建出差异化的治疗路径。临床医生现在拥有更广泛的选择，可以根据每位患者的个别需求量身定制干预措施，在即时、按需的干预与能够改善生活品质的长期预防策略之间取得平衡。同时，商业性成功越来越依赖在对照试验之外，透过真实世界的疗效、减少对急性护理的依赖以及以患者为中心的结果来证明其价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依治疗类型分類的遗传性血管性水肿治疗市场

  • 一经请求
    • 缓激肽受体拮抗剂
    • 激肽释放酶抑制剂
    • 血浆来源的C1抑制剂
    • 重组C1抑制剂
  • 预防性治疗
    • 单株抗体
    • 口服小分子化合物
    • 血浆来源的C1抑制剂

第九章：遗传性血管性水肿治疗市场：依药物类别划分

  • 缓激肽受体拮抗剂
  • 激肽释放酶抑制剂
  • 单株抗体
  • 血浆来源的C1抑制剂
  • 重组C1抑制剂

第十章：遗传性血管性水肿疗法市场：依给药途径划分

  • 静脉
  • 口服
  • 皮下

第十一章：遗传性血管性水肿治疗市场：依通路划分

  • 医院药房
  • 零售药房
  • 网路药房

第十二章：遗传性血管性水肿治疗市场：依最终用户划分

  • 诊所
  • 居家照护
  • 医院

第十三章：遗传性血管性水肿治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：遗传性血管性水肿治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：遗传性血管性水肿治疗药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国遗传性血管性水肿治疗药物市场

第十七章：中国遗传性血管性水肿治疗药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Apellis Pharmaceuticals, Inc.
  • Attune Pharmaceuticals, Inc.
  • Biocryst Pharmaceuticals, Inc.
  • BioMarin Pharmaceutical Inc.
  • CSL Behring LLC
  • Ionis Pharmaceuticals, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Novartis AG
  • Pharming Group NV
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-742BD517F714

The Hereditary Angioedema Therapeutics Market was valued at USD 40.77 billion in 2025 and is projected to grow to USD 43.49 billion in 2026, with a CAGR of 6.45%, reaching USD 63.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 40.77 billion
Estimated Year [2026] USD 43.49 billion
Forecast Year [2032] USD 63.15 billion
CAGR (%) 6.45%

A concise integrated overview of clinical, commercial, and regulatory dynamics that are redefining hereditary angioedema management and strategic priorities

Hereditary angioedema remains a distinct therapeutic area characterized by episodic, potentially life-threatening swelling driven by dysregulated bradykinin-mediated pathways. Clinical management has evolved from acute, hospital-centered interventions to a continuum that emphasizes rapid on-demand relief combined with proactive prophylactic strategies to reduce attack frequency and severity. The interplay between novel targeted therapies, evolving administration routes, and shifting care settings now shapes clinical decision-making, payer negotiations, and patient adherence patterns.

This executive summary synthesizes contemporary clinical, commercial, and regulatory dynamics that are reshaping how clinicians, manufacturers, and health systems approach hereditary angioedema. It highlights transformational therapeutic innovations, evaluates the ripple effects of recent trade policy adjustments, and distills segmentation and regional trends that influence go-to-market tactics. The goal is to provide decision-makers with a concise, integrated perspective that supports evidence-driven prioritization of investments, partnerships, and product positioning across both acute and preventive care pathways.

How recent therapeutic innovations, administration shifts, and evidence generation are collectively transforming clinical pathways and commercial value propositions in hereditary angioedema

The past decade has witnessed transformative shifts across drug modalities, care delivery, and patient expectations that are converging to reshape the hereditary angioedema ecosystem. Therapeutic innovation has progressed beyond traditional plasma-derived replacement approaches to include targeted biologics and small molecules designed to interrupt kallikrein activity or block bradykinin signaling, enabling both efficacious on-demand relief and sustained prophylaxis. These advances have introduced new choices for clinicians, but they have also raised the bar for demonstrating comparative effectiveness, tolerability, and real-world adherence.

Concurrently, patient-centric delivery innovations-such as oral prophylactic agents and subcutaneous formulations-have accelerated the movement of care from inpatient settings into clinics and home environments. This decentralization increases the importance of patient education, remote monitoring, and support programs that ensure correct administration and timely escalation of care during breakthrough attacks. Payers and health systems now demand robust value narratives that combine clinical outcomes with evidence of reduced acute care utilization. As a result, manufacturers are investing in longitudinal evidence generation, patient-reported outcomes, and economic modeling to substantiate therapeutic differentiators and to support formulary positioning.

Finally, collaborative pathways between academic centers, specialty pharmacies, and advocacy groups are amplifying real-world data capture and enabling pragmatic comparative analyses. Innovations in registry design, digital symptom tracking, and pharmacovigilance are creating richer evidence streams that inform treatment sequencing and guideline evolution. Taken together, these shifts signal a maturing therapeutic landscape where scientific innovation is tightly linked to delivery model redesign and value demonstration.

Assessing how recent tariff policy adjustments can ripple through supply chains, manufacturing choices, clinical administration, and access pathways for hereditary angioedema treatments

The introduction of adjustment in trade policy and tariff frameworks can materially influence supply chain economics, product availability, and strategic sourcing decisions for therapeutics that rely on complex biologic production or specialized raw materials. Tariff changes affecting intermediate components, cold-chain transport, and medical device accessories elevate cost structures for manufacturers and can introduce variability in pricing across distribution channels. Anticipating such shifts, stakeholders are reevaluating supplier diversification, regional manufacturing footprints, and inventory strategies to preserve continuity of care for patients dependent on time-sensitive therapies.

Manufacturers that source critical inputs internationally may respond by regionalizing production or establishing contingency inventory hubs to mitigate the operational impact of tariff-driven cost pressures. These actions, while stabilizing supply, require capital allocation and lead-time adjustments that influence product launch sequencing and contracting negotiations with payers and providers. For clinically administered treatments, increased logistics complexity can also affect hospital and clinic procurement practices, leading institutions to favor therapies with simpler storage and handling requirements when clinically appropriate.

Moreover, tariffs can indirectly shape competitive dynamics by altering total delivered cost across routes of administration. For example, therapies that reduce dependence on intravenous administration and complex hospital services may present an advantage in environments where tariffs elevate the cost of imported infusion-related components. In parallel, specialty pharmacies and home care providers will need to adapt their procurement and reimbursement strategies to reflect any incremental cost burdens, working with manufacturers and payers to preserve patient access while maintaining sustainable margins. Ultimately, productive engagement between industry, policy stakeholders, and supply chain partners will be essential to navigate tariff-driven disruptions and to safeguard stable access to lifesaving therapeutics.

Deconstructing the therapeutic ecosystem through treatment intent, pharmacologic class, administration routes, distribution channels, and end-user care settings to inform strategy

Segmentation in this therapeutic area frames commercial and clinical decision-making by delineating treatment intent, pharmacology, administration route, distribution pathways, and end-user environments. Based on treatment type, emphasis is placed on both On Demand interventions and Prophylaxis strategies; On Demand interventions include bradykinin receptor antagonists, kallikrein inhibitors, plasma derived C1 inhibitors, and recombinant C1 inhibitors, while Prophylaxis strategies encompass monoclonal antibodies, oral small molecules, and plasma derived C1 inhibitors. This treatment-type taxonomy clarifies the therapeutic trade-offs between immediate symptomatic control and long-term attack prevention, informing clinical sequencing and patient-tailored regimens.

Based on drug class, analyzers consider bradykinin receptor antagonists, kallikrein inhibitors, monoclonal antibodies, plasma derived C1 inhibitors, and recombinant C1 inhibitors as distinct mechanisms with different safety profiles, administration requirements, and evidence expectations. These pharmacologic categorizations drive differential value messages to payers and clinicians, particularly when head-to-head comparative evidence remains limited. Based on route of administration, distinctions among intravenous, oral, and subcutaneous formats materially influence site-of-care economics, patient adherence, and design of support services, since intravenous therapies often require facility-based delivery whereas oral and subcutaneous options facilitate clinic or home administration.

Distribution channel segmentation further shapes commercial execution and access pathways, with hospital pharmacies, retail pharmacies, and specialty pharmacies each playing specific roles in dispensing, reimbursement navigation, and patient support. Hospital pharmacies remain central for acute administration and inpatient management, retail pharmacies provide convenience for routine refills and community access, and specialty pharmacies deliver care coordination and claims expertise for high-cost or complex therapies. Finally, end-user segmentation across clinic, home care, and hospital settings underscores the growing importance of decentralized care models, where home infusion or self-administered prophylaxis requires robust training, monitoring, and safety net arrangements to preserve clinical outcomes and patient confidence.

How regional healthcare architectures, payer processes, and care delivery models drive differentiated adoption patterns across the Americas, EMEA, and Asia-Pacific

Geography continues to shape clinical practice patterns, regulatory pathways, reimbursement models, and adoption velocity across hereditary angioedema therapeutics. In the Americas, established specialty care networks, a strong private-sector payer presence, and concentrated centers of expertise often accelerate uptake of novel prophylactic agents and support robust specialty pharmacy integration. Clinical pathways in this region emphasize rapid on-demand access paired with growing home-based prophylaxis programs, reflecting both patient preference and system incentives to reduce acute care utilization.

In Europe, Middle East & Africa, heterogeneity in national health system structures, access criteria, and procurement mechanisms results in variable adoption timelines. Countries with centralized health technology assessment processes commonly require comprehensive evidence packages that demonstrate real-world effectiveness and cost implications, while other jurisdictions may prioritize managed access arrangements or named-patient programs to bridge access during evidence development. Across these markets, clinician networks and regional centers of excellence play a pivotal role in shaping guideline interpretation and treatment sequencing.

Asia-Pacific presents a diverse landscape where regulatory modernization, expanding specialty care capacity, and rising patient advocacy are accelerating interest in both on-demand and prophylactic options. In several markets, the growth of outpatient infusion centers, specialty pharmacy capabilities, and digital health platforms is enabling broader adoption of self-administration approaches. Across all regions, cross-border collaborations, multinational clinical registries, and real-world evidence platforms are increasing the comparability of outcomes and informing multinational market entry strategies and value demonstration efforts.

Examining how innovators and incumbents align clinical differentiation, distribution partnerships, and real-world evidence to secure durable commercial advantage

Company strategies in hereditary angioedema increasingly center on differentiated clinical profiles, delivery innovations, and evidence generation that supports payer and provider value propositions. Established biopharmaceutical companies with experience in biologics tend to leverage scale, integrated manufacturing, and existing commercial networks to introduce monoclonal antibodies and recombinant enzymes, while smaller biotechnology firms focus on highly targeted mechanisms, novel oral molecules, or formulation improvements that enable subcutaneous use and home administration. Strategic partnerships between platform innovators and specialty distributors are common, as they combine clinical differentiation with execution capabilities across complex supply chains.

Commercial playbooks emphasize curated patient journeys, including adherence support, nurse-led training for self-administration, and outcomes tracking that can validate therapeutic benefits in routine practice. Companies are also prioritizing lifecycle management initiatives-such as new formulations, label expansions, and pediatric data generation-to extend clinical utility and address underserved subpopulations. In competitive landscapes where multiple classes coexist, successful firms articulate clear comparative hypotheses and invest in head-to-head or pragmatic registries to substantiate real-world advantages. Finally, manufacturing resilience and supply chain transparency are treated as strategic differentiators, particularly for therapies requiring cold chain logistics or plasma-derived inputs.

Actionable tactics for aligning clinical evidence, decentralized delivery, supply chain resilience, and payer engagement to accelerate adoption and sustain access

Industry leaders should prioritize an integrated approach that aligns therapeutic differentiation with pragmatic delivery models and robust evidence generation. First, invest in longitudinal real-world studies and patient-reported outcome instruments to demonstrate not only clinical efficacy but also reductions in healthcare utilization and improvements in daily functioning. These data assets strengthen contracting conversations with payers and create a defensible narrative for preferential placement when clinical differences are nuanced. Second, optimize product formats and support services to enable decentralization of care-developing training modules, telehealth support, and home administration checklists will reduce barriers to adoption and improve adherence.

Third, proactively assess supply chain exposure to tariff shifts and consider regional manufacturing or inventory buffering for critical components to preserve continuity of care. Engaging early with logistics partners and integrating scenario planning into commercial launch timelines will mitigate disruption risk. Fourth, establish targeted payer engagement strategies that map value stories to specific distribution channels and end-user contexts; specialty pharmacies and hospital procurement teams require differentiated evidence and operational assurances to endorse new therapies. Finally, pursue collaborative research with centers of excellence and patient advocacy organizations to accelerate enrollment in registries and to refine outcome measures that matter most to patients and payers, reinforcing both clinical and commercial positioning.

A transparent mixed-methods evidence synthesis combining clinical literature, stakeholder interviews, registries, and trade analyses to support strategic decision-making

The research underpinning this analysis combined a structured review of peer-reviewed clinical literature, regulatory documents, and guidelines with expert interviews across clinical, payer, and commercial stakeholders. Data abstraction prioritized therapeutic mechanism, administration route, documented outcomes, safety signals, and patterns of care delivery. Real-world insights were synthesized from clinical registries and anonymized claims narratives to illuminate treatment pathways and site-of-care transitions without relying on proprietary market sizing datasets.

Qualitative inputs were validated through cross-stakeholder discussions to reconcile clinical practice variations and to surface emergent trends in patient preferences and distribution logistics. Supply chain and tariff-related analyses drew from customs regimes, trade policy announcements, and industry operational reports to characterize plausible impacts on manufacturing and distribution. Throughout the methodology, emphasis was placed on triangulating evidence sources, documenting assumptions, and highlighting areas where data gaps warrant targeted post-market studies or registries to inform long-term strategy.

Summarizing why integrated clinical innovation, supply chain resilience, and real-world evidence are essential to translate therapeutic advances into sustained patient access

The therapeutic landscape for hereditary angioedema is at an inflection point where mechanistic innovation, administration flexibility, and new evidence paradigms converge to create differentiated care pathways. Clinicians now have a broader armamentarium to tailor interventions to individual patient needs, balancing immediate on-demand interventions against longer-term prophylactic strategies that can improve quality of life. At the same time, commercial success increasingly depends on demonstrating value beyond controlled trials-through real-world effectiveness, reduced acute care dependency, and patient-centered outcomes.

Operational resilience is equally vital: manufacturers and distributors must manage supply chain complexity, adapt to policy shifts, and ensure that evolving formulations reach patients in clinic and home settings reliably. Stakeholders who integrate clinical, logistical, and economic perspectives into a unified strategy will be best positioned to translate therapeutic advances into sustainable patient benefit and commercial viability. Ongoing collaboration across clinicians, payers, advocacy groups, and manufacturers will be essential to refine guidelines, capture meaningful outcomes, and expand equitable access to innovative therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hereditary Angioedema Therapeutics Market, by Treatment Type

  • 8.1. On Demand
    • 8.1.1. Bradykinin Receptor Antagonist
    • 8.1.2. Kallikrein Inhibitor
    • 8.1.3. Plasma Derived C1 Inhibitor
    • 8.1.4. Recombinant C1 Inhibitor
  • 8.2. Prophylaxis
    • 8.2.1. Monoclonal Antibody
    • 8.2.2. Oral Small Molecule
    • 8.2.3. Plasma Derived C1 Inhibitor

9. Hereditary Angioedema Therapeutics Market, by Drug Class

  • 9.1. Bradykinin Receptor Antagonist
  • 9.2. Kallikrein Inhibitor
  • 9.3. Monoclonal Antibody
  • 9.4. Plasma Derived C1 Inhibitor
  • 9.5. Recombinant C1 Inhibitor

10. Hereditary Angioedema Therapeutics Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Hereditary Angioedema Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Retail Pharmacies
  • 11.3. Online Pharmacies

12. Hereditary Angioedema Therapeutics Market, by End User

  • 12.1. Clinic
  • 12.2. Home Care
  • 12.3. Hospital

13. Hereditary Angioedema Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hereditary Angioedema Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hereditary Angioedema Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Hereditary Angioedema Therapeutics Market

17. China Hereditary Angioedema Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Apellis Pharmaceuticals, Inc.
  • 18.6. Attune Pharmaceuticals, Inc.
  • 18.7. Biocryst Pharmaceuticals, Inc.
  • 18.8. BioMarin Pharmaceutical Inc.
  • 18.9. CSL Behring LLC
  • 18.10. Ionis Pharmaceuticals, Inc.
  • 18.11. KalVista Pharmaceuticals, Inc.
  • 18.12. Novartis AG
  • 18.13. Pharming Group N.V.
  • 18.14. Sanofi S.A.
  • 18.15. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 155. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 179. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 180. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 187. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 188. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)